Zobrazeno 1 - 10
of 53
pro vyhledávání: '"A.J. Pilgrim"'
Publikováno v:
Neurology. 47:361-365
We compared the efficacy and safety of subcutaneous (SC) sumatriptan (6 mg) with that of dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg) in the acute treatment of migraine.Two hundred sixty-six adult migraineurs (International Headache
Publikováno v:
European Neurology. 33:310-315
Sumatriptan, a specific 5-hydroxytryptamine agonist, is a novel acute treatment for migraine. The efficacy and safety profiles of sumatriptan have previously been demonstrated in several controlled short-term studies. However, because migraine is a r
Autor:
M.R. Jackson, Oliver N. Keene, R.J.N. Tanner, J.C.C Talbot, C.A. Endersby, W. Feniuk, Patrick P.A. Humphrey, V. Pfaffenrath, A.J. Pilgrim, N.S. Baber, LF Lacey, J.W. Lance, A.S. Marriott, E.G. Brown, R.N. Smith, M.L. Tucker, P.A. Fowler, M. Thomas
Publikováno v:
European Neurology. 31:300-305
Three oral doses of sumatriptan, 100, 200 and 300 mg, given as dispersible tablets, were compared in the acute treatment of migraine in a double-blind, placebo-controlled, parallel-group study of 1,13
Autor:
Patrick P.A. Humphrey, M.L. Tucker, J.W. Lance, M.R. Jackson, V. Pfaffenrath, Oliver N. Keene, R.N. Smith, R.J.N. Tanner, P.A. Fowler, M. Thomas, W. Feniuk, A.S. Marriott, E.G. Brown, L.F. Lacey, A.J. Pilgrim, J.C.C Talbot, N.S. Baber, C.A. Endersby
Publikováno v:
European Neurology. 31:332-338
A double-blind, randomized, multicentre, parallel-group study was carried out to compare intranasal sumatriptan with placebo in the treatment of migraine. Seventy-four patients (37 in each treatment group) were recruited into the study. Patients rece
Autor:
A.J. Pilgrim
Publikováno v:
European Neurology. 31:295-299
The clinical development of sumatriptan has involved large international multicentre trials. To allow comparison of results obtained in a variety of clinical settings, great emphasis was placed on the use of consistent methodology across the programm
Autor:
M.R. Jackson, Oliver N. Keene, R.J.N. Tanner, W. Feniuk, V. Pfaffenrath, LF Lacey, R.N. Smith, J.C.C Talbot, P.A. Fowler, J.W. Lance, C.A. Endersby, M. Thomas, Patrick P.A. Humphrey, A.S. Marriott, E.G. Brown, A.J. Pilgrim, M.L. Tucker, N.S. Baber
Publikováno v:
European Neurology. 31:323-331
The efficacy and safety of sumatriptan, a selective 5-HT1 like receptor agonist, were studied in a randomized, double-blind, placebo-controlled, parallel-group, multicentre, multinational c
Autor:
A.J. Pilgrim, M.R. Jackson, Patrick P.A. Humphrey, J.W. Lance, N.S. Baber, R.N. Smith, Oliver N. Keene, P.A. Fowler, R.J.N. Tanner, V. Pfaffenrath, C.A. Endersby, W. Feniuk, A.S. Marriott, E.G. Brown, LF Lacey, J.C.C Talbot, M. Thomas, M.L. Tucker
Publikováno v:
European Neurology. 31:306-313
In a multinational, placebo-controlled, double-blind, parallel-group study of oral sumatriptan (GR43175), given as a dispersible tablet, in the acute treatment of migraine, 149 pati
Publikováno v:
Cephalalgia : an international journal of headache. 14(5)
Oral sumatriptan in a dose of 100 mg aborts about 60% of migraine attacks within 2 h, but the headache may recur within 24 h. We investigated: (i) the incidence of headache recurrence after oral sumatriptan, (ii) whether a second tablet of sumatripta
Publikováno v:
Journal of the neurological sciences. 114(1)
Sumatriptan is a selective 5-HT1-like agonist, which is effective in the treatment of migraine and cluster headache. It has been rigorously assessed in clinical trials involving over 7000 patients who have treated over 35,000 migraine attacks. Both s